1. Home
  2. ANET vs NVO Comparison

ANET vs NVO Comparison

Compare ANET & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arista Networks Inc.

ANET

Arista Networks Inc.

N/A

Current Price

$200.14

Market Cap

238.0B

ML Signal

N/A

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

N/A

Current Price

$43.24

Market Cap

199.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ANET
NVO
Founded
2004
1923
Country
United States
Denmark
Employees
N/A
N/A
Industry
Computer Communications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
238.0B
199.4B
IPO Year
2014
2001

Fundamental Metrics

Financial Performance
Metric
ANET
NVO
Price
$200.14
$43.24
Analyst Decision
Strong Buy
Hold
Analyst Count
17
11
Target Price
$175.18
$51.00
AVG Volume (30 Days)
4.4M
8.4M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
3.19%
EPS Growth
23.32
N/A
EPS
1.75
N/A
Revenue
$9,005,700,000.00
N/A
Revenue This Year
$29.10
N/A
Revenue Next Year
$21.80
$3.70
P/E Ratio
$112.38
$13.60
Revenue Growth
28.60
N/A
52 Week Low
$114.52
$35.12
52 Week High
$214.89
$64.16

Technical Indicators

Market Signals
Indicator
ANET
NVO
Relative Strength Index (RSI) 53.97 33.56
Support Level $182.05 $41.05
Resistance Level $203.40 $48.15
Average True Range (ATR) 6.08 0.79
MACD -0.44 -0.37
Stochastic Oscillator 61.91 1.99

Price Performance

Historical Comparison
ANET
NVO

About ANET Arista Networks Inc.

Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three-fourths of its sales from North America.

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: